Homocysteine, a sulphur amino acid, is a branch-point intermediate of methionine metabolism. It can be degraded in the transsulphuration pathway to cystathionine, or remethylated to methionine via the remethylation pathway. In both pathways, major genetic defects that cause enzyme de ciencies are associated with very high plasma homocysteine concentrations and excretion of homocystine into the urine. Mildly elevated plasma homocysteine concentrations are thought to be an independent and graded risk factor for both arterial occlusive disease and venous thrombosis. Genetic defects in genes encoding enzymes involved in homocysteine metabolism, or depletion of important cofactors or (co)substrates for those enzymes, including folate, vitamin B 12 and vitamin B 6 , may result in elevated plasma homocysteine concentrations. Plasma homocysteine concentrations are also in uenced by dietary and lifestyle factors. In the last decade, several studies have been conducted to elucidate the genetic determinants of hyperhomocysteinaemia in patients with cardiovascular disease. We report on both environmental and genetic determinants of hyperhomocysteinaemia and give a detailed overview of all the genetic determinants that have been reported to date.
Introduction
About 30 years ago, McCully postulated that mildly elevated homocysteine concentrations could increase the risk of cardiovascular disease 1 after observing artery wall lesions in two di¡erent metabolic disorders of methionine metabolism which resulted in elevated plasma homocysteine concentrations.
Since then many studies have been conducted to investigate whether elevated plasma homocysteine concentrations are associated with an increased risk of cardiovascular disease. A modest elevation of plasma homocysteine concentration, commonly referred to as hyperhomocysteinaemia, is generally, 3, 4 although not universally, 5, 6 accepted as an independent and graded risk factor for both arterial occlusive diseases and venous thrombosis. 7, 8 In this review, we report on both environmental and genetic determinants of hyperhomocysteinaemia and give a detailed overview of all the genetic determinants that have been reported to date.
Homocysteine metabolism
Homocysteine is a sulphur amino acid that is formed by the demethylation of the essential amino acid methionine via S-adenosylmethionine (AdoMet) and S-adenosylhomocysteine (AdoHcy) (see Fig. 1 ). Methionine adenosyltransferase catalyses the formation of AdoMet, which is the methyl donor in numerous reactions (e.g. methylation of DNA, RNA, hormones and lipids). The transmethylation reactions form AdoHcy, which is an inhibitor of many methyltransferases. Adenosine and homocysteine are formed from the hydrolysis of AdoHcy by S-adenosylhomocysteine hydrolase. Homocysteine can be further metabolized in two pathways: it may be irreversibly degraded to cystathionine and cysteine in the transsulphuration pathway, or remethylated to methionine in the so-called remethylation pathway.
Transsulphuration
The ¢rst step in the transsulphuration pathway is the condensation of homocysteine and serine to give cystathionine. Cystathionine b-synthase (CBS) catalyses this initial step and requires pyridoxal 5'-phosphate (PLP, the active form of vitamin B 6 ) for its activity. Cystathionine is subsequently hydrolysed to cysteine by another PLP-requiring enzyme, g-cystathionase. These enzymatic steps are limited to the liver and kidney.
Remethylation
Homocysteine can be remethylated to methionine by two di¡erent enzymatic reactions: methionine synthase (MS), with 5-methyltetrahydrofolate (5-methyl-THF) as methyl donor; or betaine-homocysteine methyltransferase (BHMT), with betaine (trimethylglycine) as methyl donor. MS is dependent on methylcobalamin (a biologically active form of vitamin B 12 ) as a cofactor for its enzymatic activity. 5-Methyl-THF is formed upon the reduction of 5,10-methylenetetrahydrofolate, a reaction that is catalysed by the enzyme 5,10-methylenetetrahydrofolate reductase (MTHFR). MTHFR uses £avin adenine dinucleotide (FAD; the active form of vitamin B 2 ) as cofactor. 9 The reversible conversion of serine and tetrahydrofolate (THF) to glycine and 5,10-methylene-THF is catalysed by serine hydroxymethyltransferase (SHMT), another PLP-dependent enzyme in homocysteine metabolism. Methylenetetrahydrofolate dehydrogenase (MTHFD) has several enzymatic properties and catalyses three sequential reactions in the interconversion of one-carbon derivatives of THF. The remethylation by BHMT occurs primarily in the liver and kidney, whereas folate -and vitamin B 12 -dependent remethylation of homocysteine take place in every cell of the human body apart from red blood cells (RBCs).
B vitamins as cofactors
Several B vitamins serve as cofactors in homocysteine metabolism: PLP (vitamin B 6 ) as a cofactor for CBS, gcystathionase and SHMT; methylcobalamin (vitamin B 12 ) for MS; and FAD (vitamin B 2 ) for MTHFR. In addition, 5-methyl-THF, the active form of folate, is required by MS as a co-substrate; it is formed upon reduction of 5,10-methylene-THF by MTHFR.
Vitamin B 6
Vitamin B 6 consists of di¡erent related forms: pyridoxine, pyridoxal and pyridoxamine, and their phosphate esters. 10 Vitamin B 6 is absorbed in the upper small intestine by di¡usion and transported to the liver where phosphorylation takes place. 11 PLP is the main circulating form which, bound by albumin, is exported from the liver 12 and is the only active form that can be used by enzymes. Uptake into tissue is by extracellular dephosphorylation followed by metabolic trapping intracellularly as PLP. 13 
Vitamin B 12
Dietary vitamin B 12 is ¢rst released from food by pepsin. In the stomach it is bound to haptocorrin. Vitamin B 12 is released from haptocorrin by pancreatic proteases and is subsequently bound to intrinsic factor (IF). 14 In the ileum, the IF-vitamin B 12 complex binds to its receptor cubulin 15 and is absorbed by receptormediated endocytosis. Vitamin B 12 is transported in the circulation by the protein transcobalamin (TC), which also delivers vitamin B 12 to the cells. 16 The vitamin B 12 -TC complex is taken up by receptormediated endocytosis via the receptor TC-R, 16 which is expressed on the cell surface of most tissues. Intracellularly, vitamin B 12 is released and metabolized in di¡erent steps before it can function as a methyl carrier in homocysteine metabolism. Various inborn errors of metabolism involving each of these necessary steps have been described. These have been subdivided into di¡erent groups on the basis of complementation experiments: cobalamin (cbl) F, cblC/ D, cblE and cblG.
Folate
Folate occurs naturally as a mixture of polyglutamate derivatives. 17 However, dietary folate polyglutamates must be hydrolysed to monoglutamates in the intestine prior to absorption. Folylpoly-g-glutamate carboxypeptidase, which is anchored to the intestinal brush border membrane, hydrolyses these polyglutamylated folates into monoglutamylfolate s, which can be actively transported across the membrane by the reduced folate carrier. Once inside the cell the monoglutamylfolates have to be converted back to polyglutamates by folylpolyglutamate synthetase, since the enzymes that utiliz e folate as cofactor have higher a¤nities for polyglutamated folate species. 18 Folylpolyglutamates cannot cross or are only poorly transported across cell membranes and are important for intracellular retention of folates, whereas monoglutamates, in particular methyl-THF, are the transport form of the vitamin.
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Determinants of homocysteine concentrations
Disturbances in intracellular homocysteine metabolism may lead to elevated plasma homocysteine concentrations. These defects can have a genetic background, such as an inherited enzyme de¢ciency, a variation in the genes encoding these enzymes or an environmental aetiology (see Box 1), such as diet and lifestyle factors, which could lead to depletion of important cofactors or substrates involved in homocysteine metabolism or even inhibited enzyme activity.
Environmental factors
Renal function
A strong determinant of homocysteine concentration is kidney function. 19 Patients with renal failure have markedly elevated plasma homocysteine concentrations, but the underlying pathophysiological mechanism is not completely understood. However, the extent to which homocysteine is excreted in the urine is very low in these patients. It is possible that homocysteine metabolism is in£uenced or even regulated by kidney function, or that the kidney itself converts a major amount of homocysteine present in blood. Serum creatinine concentrations, as an indicator of altered renal function, have been shown to be strongly positively associated with homocysteine concentrations. 20 
Age and sex
Increasing age 21, 22 and male gender 22, 23 have been found to be associated with increased homocysteine concentrations, although the in£uence of gender was found to be most pronounced in the lower concentration range. 23 The sex di¡erence may be explained by vitamin status, 24 muscle mass and hormonal factors. 25 
Dietary factors
Several dietary factors have been investigated as possible determinants of homocysteine concentrations in the Hordaland Homocysteine Study, 26 the Framingham O¡spring Cohort 20 and the MORGEN Study. 27 Obviously, folate status and that of other B vitamins are important determinants of homocysteine concentrations in the general population since they play an important role in homocysteine metabolism as substrate or cofactors. Both folic acid supplementation and a high dietary folate intake 22,24,28^30 have been shown to decrease plasma homocysteine concentrations and this relationship was found to be dose-responsive. However, folic acid in supplements appears to be more e¡ective than natural food folate in improving folate status, 22 31 Regular users of multivitamin preparations also have lower homocysteine concentrations, 23 although the intake of supplements that contain only vitamin B 6 and cobalamin, but not folic acid, was not related to homocysteine concentrations. 22 In the Framingham O¡spring Cohort, folate and vitamin B 12 concentrations were associated with low homocysteine concentrations, whereas dietary vitamin B 12 intake was not. 20 In a Dutch population, folate intake was the only B vitamin that was independently and inversely associated with plasma homocysteine concentrations. 27 
Lifestyle factors
Co¡ee consumption and smoking have also been associated with increased homocysteine concentrations 32^34 and, in combination with low folate intake, greatly exceeded the e¡ect of each factor alone. 22 The association between alcohol consumption and homocysteine appears J-shaped: 35 alcoholics have high homocysteine concentrations, 36 whereas moderate alcohol users have lower homocysteine concentrations compared with non-drinkers. 37 The e¡ect of alcohol consumption was also shown to be dependent on the type of alcoholic beverage. 38 
Miscellaneous
Several drugs, such as antiepileptic drugs, methotrexate or lipid-lowering drugs, have been shown to increase plasma homocysteine to mildly elevated concentrations. 39 Also, lack of exercise, 40 body mass index 20 and cardiovascular risk factors such as cholesterol 40, 41 and blood pressure 42 have been mentioned as determinants of homocysteine concentrations.
Genetics of homocysteine Homocystinuria
Severe hyperhomocysteinaemia or homocystinuria, which is characterized by the accumulation of homocysteine in the blood and homocysteine excretion in the urine, was ¢rst described by Carson and Neill. 43 CBS de¢ciency is the most common cause of homocystinuria. 44 The most common clinical features of CBS de¢ciency include dislocation of the optic lens, osteoporosis, marfanoid features, mental retardation and an early onset of vascular disease. Most CBSde¢cient patients have clearly reduced CBS enzyme activity in extracts of cultured ¢broblasts. In addition to homocysteine, methionine accumulates in the body and is excreted via the kidney. More than 100 mutations in the CBS gene have been described in CBSde¢cient patients, and most of them have been found to decrease CBS enzyme activity signi¢cantly. 45 The two most frequent mutations are 833T!C (I278T), which accounts for about one-quarter of all homocystinuric alleles and is the most common cause of homocystinuria in the Netherlands, 46 and 919G!A (G307S), which is the leading cause of homocystinuria in Ireland. 47 Reduced MS activity due to inborn errors of methylcobalamin transport or synthesis have been described as causing severe hyperhomocysteinaemia, but such cases are very rare. 48, 49 In MTHFR de¢ciency, the clinical severity is correlated with the degree of enzyme de¢ciency, the most common clinical manifestation of MTHFR de¢ciency being developmental delay. 48 In contrast to CBS de¢-ciency, the major biochemical ¢ndings are moderate homocystinuria and homocystinaemia, with low or relatively normal concentrations of plasma methionine; the excretion of homocysteine is much less than in homocystinuria due to CBS de¢ciency. De¢ciency of CBS and MTHFR as well as of MS are associated with an increased risk for vascular disease.
Hyperhomocysteinaemia
In a study among family members of 21 post-load hyperhomocysteinaemic vascular patients, it was shown that, after exclusion of individuals with vitamin de¢ciencies, liver and renal diseases, the number of family members with hyperhomocysteinaemia was much higher than might be expected in the normal population. 50 Furthermore, post-load mild hyperhomocysteinaemia was established in at least one other family member in 71% of the families, indicating a strong genetic basis for hyperhomocysteinaemia. The conclusion that hyperhomocysteinaemia is, at least partially, genetically based is in line with previous reports. 51^55 Thus, genetic variation in genes coding for enzymes involved in the regulation of homocysteine may a¡ect plasma homocysteine concentrations.
Obviously, the genes coding for the enzymes MTHFR, CBS and MS are possibilities because of their direct catalytic involvement in homocysteine and folate metabolism, but other enzymes involved in homocysteine metabolism, such as BHMT, SHMT and MTHFD, are also important candidates. In addition, enzymes involved in the metabolism of cofactors such as vitamin B 6 or vitamin B 12 , or substrates such as folate, could be of great importance in maintaining homocysteine homeostasis.
Numerous variations in genes involving homocysteine metabolism have already been investigated (seeTable 1), of which 677C!T (A226V) in the MTHFR gene is most extensively described. The requirements of high-throughput and ease of a polymorphism genotyping method will become increasingly important. A large number of good genotyping methods are available; these have been extensively and systematically explained in two recent review articles. 56, 57 Cystathionine b-synthase In 1985, Boers et al. 58 reported that heterozygosity for CBS de¢ciency accounted for the hyperhomocysteinaemia in patients with vascular disease. Subsequently, Clarke et al. 59 reported a similar observation. However, results from Mudd et al. 60 showed no statistically signi¢cant increase in the incidence of heart attacks or strokes in parents and grandparents of homocystinuric children. Furthermore, the estimated frequency of heterozygosity for CBS de¢ciency is much lower than the frequency of mild hyperhomocysteinaemia, which is approximately 10-20% in the normal population and is too low to account for the number of vascular patients with mild hyperhomocysteinaemia. 61 In addition, the ¢nding of decreased CBS activity in cultured ¢broblasts from hyperhomocysteinaemic patients with vascular disease in the range of obligate heterozygotes could not be reproduced 62, 63 and still requires clari¢cation. The isolation and characterization of CBS cDNA by Kraus et al. 64 permitted the molecular genetic analysis of CBS cDNA in patients with vascular disease. In 60 Dutch patients with arterial occlusive disease, we were unable to detect the 833C!T (I278T) mutation in the CBS gene, a mutation that is present in approximately 50% of alleles of Dutch homozygotes for CBS de¢ciency. 63 In a comparable study, Gallagher et al. 65 did not detect thè Celtic' 919G!A (G307S) mutation in 100 patients with vascular disease, whereas this mutation is the predominant cause of homocystinuria in the Irish population. 47 These observations were supported by the results of Kozich et al., 66 who analysed the CBS cDNA of four hyperhomocysteinaemic patients with peripheral arterial occlusive disease and decreased CBS activity in extracts of cultured ¢broblasts. Neither pathogenic mutations nor a defective stimulation by Adomet were noticed as a possible cause of decreased enzymatic activity. In summary, all genetic studies that have been performed to date have failed to detect any involvement of heterozygosity for CBS de¢ciency in hyperhomocysteinaemia and premature vascular disease. 
844ins68
Several polymorphisms have been reported in the CBS gene. A 68-base pair (bp) insertion (844ins68) was ¢rst reported in a patient with homocystinuria, 67 but this subsequently appeared to be a common variant. 68 This insertion always segregates in cis with the 833T!C mutation, but both are skipped by alternative splicing of the CBS mRNA. 68, 69 The 844ins68 polymorphism does not seem to a¡ect CBS enzyme activity 69 or homocysteine concentration, 69, 70 although, in 1999, Tsai et al. reported that carriers of the 844ins68 insertion had even lower postmethionine -load increases when vitamin B 6 concentrations were below the sample median of 38¢0 nmol/ L. 71 
31-base pair variable number of tandem repeats polymorphism
In 1998, Kraus et al. described the complete nucleotide sequence of the human CBS gene and reported a variable number of tandem repeats (VNTR) polymorphism of 31 bp in intron 13. 72 However, after closer examination we found that this 31-bp VNTR spans the exon 13-intron 13 boundary and could therefore contain multiple splice donor sites, with possible repercussions on CBS protein and, consequently, function. We found that this 31-bp VNTR is associated with a signi¢cant increase in post-methionine-load homocysteine concentrations and showed evidence of alternative splicing in individuals with di¡erent VNTR genotypes. 73 In addition, we observed a negative correlation between CBS enzyme activity and an increasing number of repeat units, which corroborates the positive association between the VNTR and post-load homocysteine concentrations. We later con¢rmed the positive association between post-methionine-load homocysteine concentrations and number of repeat units in more than 1400 subjects of the Framingham O¡spring Study (Lievers et al., unpublished results) . Yang et al. 74 reported lower post-methionine-load homocysteine concentrations in the 17-18 as well as the 18-19 genotype compared with the most common 18-18 genotype.
699C!T (Y233Y) and 1080C!T (A360A)
These two silent polymorphisms in the CBS gene have been studied as possible determinants of homocysteine concentrations and risk of coronary artery disease (CAD) or as markers for possible functional variants in the CBS gene.
75^77 De Stefano et al. 75 found no association between these CBS variants and plasma homocysteine concentrations, while Aras et al. 77 reported decreased post-methionine-load homocysteine concentrations in individuals who were heterozygous or homozygous for the 699T allele compared with 699CC subjects. This association became more signi¢cant when individuals carrying 844ins68 and the 1080T allele were excluded. With regard to the 1080C!T polymorphism, the 1080T allele was associated with lower postmethionine-load homocysteine concentrations only when individuals carrying 844ins68 and the 699T allele were excluded from the analysis. Aras et al. speculated that the 699C!T and 1080C!T CBS variants may be in linkage disequilibrium with regulatory elements that upregulate CBS gene transcription. 77 In 2000, Kruger et al. 76 failed to ¢nd an association between the two silent CBS variants and homocysteine concentrations, while in their study population of 142 CAD patients and 105 controls, the homozygous 699TT individuals as well as the 1080CC subjects were signi¢cantly underrepresented in the patients. We, however, did not observe any association between homocysteine concentrations or CAD risk and the di¡erent genotypes of these two CBS variants.
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Methionine synthase
In the MS gene, a single nucleotide polymorphism was identi¢ed at position 2756 (an A to G transition, D919G). 78 Harmon et al. 79 reported a relative risk of 1¢58 [95% con¢dence interval (95% CI): 1¢14-2¢19] of the 2756AA genotype compared with the AG and GG genotypes, for having a homocysteine concentration in the top half of the distribution. Several years later, Hyndman et al. 80 calculated that the 2756AG heterozygotes were less likely to have a recurrent vascular event than the AA individuals [odds ratio (OR): 3¢4; 95% CI: 1¢09-10¢9]. Furthermore, this 2756A!G polymorphism did not a¡ect homocysteine concentrations, but the RBC folate concentrations were signi¢cantly elevated in the 2756AG heterozygotes compared with the AA subjects. Chen et al. 81 also investigated the association between this MS variant and plasma homocysteine concentrations, folate levels and risk of myocardial infarction (MI). They found a non-signi¢cant reduction of MI risk in the GG individuals compared with the AA individuals and a trend towards decreased homocysteine concentrations. In our study population of patients with cardiovascular disease and healthy controls, the 2756GG genotype was signi¢cantly associated with increased risk of coronary heart disease (CHD), whereas the AG genotype was inversely, although not signi¢cantly, associated with CHD risk. The 2756A!G polymorphism was, in our study population, not associated with fasting or post-methionine-load homocysteine concentrations (Klerk et al., unpublished results).
Methionine synthase reductase
The enzyme methionine synthase reductase (MTRR) is needed to maintain MS in its active state. Polymorphisms of MTRR might therefore in£uence homocysteine concentrations. Mutation analysis of the MTRR gene in homocystinuric patients belonging to the cblE complementation group led to the discovery of a polymorphism, an A to G substitution at bp 66 (I22M), which is common in the general population. 82 In a subsequent study, the 66GG genotype appeared to increase the risk of a neural tube defect (NTD) pregnancy outcome in women with low vitamin B 12 concentrations, while no association between the 66A!G genotype and homocysteine concentrations was reported. 82 This polymorphis m was also reported to be a risk factor for the development of premature CAD, with a relative risk of 1 ¢ 49 (95% CI: 1 ¢ 10-2 ¢ 03) in 66GG subjects compared with 66AA individuals. Again, there was no di¡erence in plasma homocysteine, plasma folate and vitamin B 12 concentrations between the three 66A!G genotypes. 83 In a study of 601 Northern Irish men, Gaughan et al. 84 established a relative risk of 1¢59 (95% CI: 1¢10-2¢25) for having a plasma homocysteine concentration in the top half of the distribution. This homocysteine-elevating e¡ect was found to be independent of serum folate, vitamin B 12 and B 6 concentrations, and the estimated e¡ect of the 66AA genotype on cardiovascular disease (CVD) risk was an approximately 4% increase compared with the 66GG genotype.
Betaine-homocysteine methyl transferase
Betaine^homocysteine methyl transferase is the enzyme which, along with MS, remethylates homocysteine to methionine, but is primarily expressed in liver and kidney. There is only one study that reported polymorphisms in the BHMT gene and the in£uence of three BHMT variants on homocysteine concentrations and CVD risk. 85 We found one variant, the 1218G!T (Q406H) substitution, in only one patient and one control in the heterozygous state. The other two variants, the 595G!A (G199S) and the 716G!A (Q239R) transitions, were found to be more frequent but showed no associations with homocysteine concentrations and were not associated with an increased CVD risk.
5,10-methylenetetrahydrofolate 677C!T (A226V)
In 1988, Kang et al. 86 detected a variant of the MTHFR enzyme which was associated with decreased enzyme activity, reduced stability after heating at 468C and increased homocysteine concentrations. A few years later these authors demonstrated that this thermolabile form of the MTHFR enzyme was more common among CVD patients (17%) than among controls (5%). 87 In our study this thermolabile MTHFR enzyme was identi¢ed in patients with di¡erent forms of premature vascular disease and was associated with fasting as well as post-methionine -load homocysteine concentrations. 62 In 1995, Frosst et al. 88 identi¢ed the single base pair substitution of C to T at nucleotide 677 to be responsible for this thermolabile MTHFR enzyme. Since then, numerous studies have been reported which investigated this MTHFR variant and its association with homocysteine concentrations and CVD risk. 89 Although an association between the 677C!T variant and elevated homocysteine concentrations was universally found, 63,65,88,90^96 an increased risk for CVD was found in only some studies. 63, 65 The association between the 677C!T variant and elevated homocysteine concentrations was reported to exist only in individuals with low folate status. 91, 92 In 1998, the hypothesis that this variant is associated with altered distribution of RBC folates was tested by a chromatographic method in vitro. 97 This method involves the analysis of RBC folates by a¤nity/high-performance liquid chromatography with electrochemical (coulometric) detection. 98 Probably due to the reduced MTHFR enzyme activity, formylated tetrahydrofolate polyglutamates were present at the expense of methyl-THF in most 677TT individuals.
Thermolabile MTHFR accounts for 25% of the mild hyperhomocysteinaemia observed in patients with vascular disease, 62 indicating that additional mutations in the MTHFR gene or other genes may also a¡ect homocysteine concentrations. Moreover, it appears that the 677TT genotype is associated with increased homocysteine concentrations only in individuals with low folate status. 91, 92 Thus, possible gene -environment interactions also play an important role in modulating plasma homocysteine concentrations.
1298A!C (E433A)
In 1998, a second common polymorphism in the MTHFR gene was described, the 1298A!C transition, which mandates an amino acid substitution of glutamate by alanine. 99 This variant was observed only in trans with the 677C!T variant and was associated with decreased MTHFR enzyme activity. We have described the associations of this 1298A!C variant with MTHFR enzyme activity, plasma homocysteine concentrations and risk of CVD. 100 We again detected a decrease in enzyme activity in individuals with the 1298AC and 1298CC genotypes, but noted no e¡ect on the thermostability of the enzyme or on plasma homocysteine concentrations. 100 Although all studies con¢rm that the 1298A!C variant is associated with decreased MTHFR activity, 99^102 supported by expression analysis in Escherichia coli, 103 an association with homocysteine concentrations has not been detected. 101,102,104^109 Probably, other factors that a¡ect homocysteine concentrations, such as nutritional status, play a role, or the decreased MTHFR enzyme activity must reach a certain threshold below which increased plasma homocysteine concentrations result.
Serine hydroxymethyl transferase
In humans, SHMT is present as two isoenzymes, one located in the mitochondria and the other in the cytoplasm. 110 In 1999, the genes for both isoforms were sequenced by our group and several variations were found in both genes. 111 One polymorphism in the cytosolic SHMT, i.e. 1420C!T (L474F), was associated with increased homocysteine concentrations and decreased plasma and RBC folate levels in 1420CC homozygotes. This polymorphism may cause a shift in distribution of the various folate derivatives, and its consequences for homocysteine/folate metabolism deserve further attention (e.g. by in vitro expression analysis).
Methylenetetrahydrofolate dehydrogenase
In the MTHFD gene, a 1958G!A (R653Q) substitution was detected by us in NTD patients and controls, but no association between this variant and homocysteine concentrations was found.
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Transcobalamin
Since TC is the transporter of vitamin B 12 to the cells and vitamin B 12 is the cofactor for MS, variation in the TC gene could a¡ect homocysteine concentrations. Several variants have been reported in the TC gene, 113^115 of which the 779C!G (P259R) polymorphism is the most studied. In1998, Namour et al. 116 reported a lower vitamin B 12 concentration as well as lower apo-TC (the proportion of TC that does not contain vitamin B 12 ) concentrations in subjects carrying the 779G allele. Several years later, they reported the same results with respect to apo-TC levels, but observed no di¡erences in vitamin B 12 concentrations between the 779C!G genotypes and concluded that the 779C allele might enhance intracellular vitamin B 12 availability. 117 McCaddon et al. 118 studied this TC 779C!G variant in 73 healthy elderly volunteers and in 71 dementia patients and observed no association with either vitamin B 12 levels or with homocysteine concentrations. Lower holo-TC (the proportion that contains vitamin B 12 ) concentrations for the 779G allele were reported byAfman et al. 119 in a population of 46 mothers with an NTD child and 73 controls, but no association between the 779C!G genotypes and homocysteine concentrations was observed. Later, in the same study population, the 779G allele was found to be associated with a lower total-TC, lower apo-TC and a lower holo-TC/total-TC ratio, suggesting that the TC 779C!G variant may result in a disturbance of vitamin B 12 binding to TC. 120 Our results 121 showed an association between 259PP individuals and decreased homocysteine concentrations only when their vitamin B 12 status was greater than 299 pmol/L. These data indicate that 259PP individuals, in particular, bene¢t from high vitamin B 12 concentrations with respect to lowering of total homocysteine, in contrast to their 259PR and 259RR peers, and suggest a gene-environment interaction between this TC variant and vitamin B 12 concentrations. We therefore also investigated whether the P259R variant in£uenced the slope of the curve relating plasma total homocysteine concentration and we observed a clear negative correlation between vitamin B 12 concentrations and plasma total homocysteine concentrations in 259PP individuals as well as in 259PR heterozygotes, whereas in subjects with the 259RR genotype no such association was found. Possibly, the 259P allele a¡ects TC transcription or binding and transport of vitamin B 12 by TC with positive repercussions on intracellular availability of vitamin B 12 . 128 Other variants in the TC gene are the M198T, I219L, S376L, 113 the Q234R, 114 the I23V 115 and the G94S, S348F and R399Q. 120 The latter four were also examined by us for their possible role in homocysteine metabolism, 121 but only the I23V polymorphism seemed to have an association with homocysteine concentrations, although this was only observed in the three homozygous 23VV individuals. These TC variants have also been studied, but none of them was found to be associated with homocysteine concentrations. 120 
Glutamate carboxypeptidase gene II
Folate plays an important role in homocysteine metabolism as the substrate for MTHFR. Dietary folates are a mixture of polyglutamylated folates and, since polyglutamates are poorly transported across membranes; they have to be hydrolysed in the digestive system to monoglutamylfolates by the action of folylpoly-gglutamate carboxypeptidase (FGCP). This enzyme is expressed by the glutamate carboxypeptidase gene II (GCPII). Variation in this gene could therefore a¡ect the intestinal absorption of dietary folates, resulting in altered blood folate levels and, consequently, homocysteine concentrations. In 2000, Devlin et al. 122 reported a C to T substitution at bp 1561 (H475Y) and determined the functional signi¢cance of this variant in vitro. Compared with FGCP activity in wild-type transfectants, the 1561C!T variant resulted in a signi¢cant reduction in FGCP activity by 53%. In addition, among 75 healthy subjects six subjects heterozygous for the 1561C!T variant had lower plasma folate levels and higher homocysteine concentrations than the 1561CC individuals. They postulated that the presence of the 1561C!T variant impaired the intestinal absorption of dietary folates, resulting in relatively low blood folate concentrations and hyperhomocysteinaemia. These results, however, were contradicted by our results. 123 We investigated the relationship between the 1561C!T variant in GCPII with fasting, post-methionine-load plasma homocysteine, folate and vitamin B 12 concentrations and the risk of CVD in 190 patients with vascular disease and 601 apparently healthy controls. Although no clear association was seen between the variant and plasma homocysteine concentrations and vitamin B 12 levels, the 1561C!T polymorphis m signi¢cantly increased both red blood cell folate and plasma folate concentrations (ANOVA Pˆ0 ¢013, test for linear trend Pˆ0 ¢03, respectively).
Reduced-folate carrier
A polymorphism, 80G!A (R27H), in the reducedfolate carrier gene, the candidate gene for 5-methyl-THF internalization within cells, was reported by Chango et al. 124 However, this variant was not associated with a change in homocysteine, plasma and RBC folate concentrations.
Other
In NTD patients, a polymorphis m in the folate receptor-a gene has been investigated, but its association with homocysteine concentrations was not investigated. 125 We also explored this folate receptor-a gene as well as the folate receptor-b gene for variants in spina bi¢da patients, mothers of a spina bi¢da child and controls, but found no polymorphis ms. 126 
Gene-gene interactions
A combination of multiple variants was studied by Tsai et al. 96 They studied the combined e¡ect of the CBS 844ins68 variant, the 677C!T MTHFR variant and the 2756A!G polymorphism in the MS gene, on either fasting or post-methionine-load homocysteine concentrations, and found that the e¡ects of these three variants were additive and therefore demonstrated a polygenic regulation of plasma homocysteine concentrations. 96 Another genetic interaction analysis was carried out by Dekou et al. 127 to determine whether the e¡ects of three variants, the MTHFR 677C!T, the MS 2756A!G and the CBS 844ins68, on homocysteine concentrations were independent and additive. They observed that the homocysteineraising e¡ect of the 677TT genotype was absent in 23 men who also carried the CBS 844ins68 insertion. In the group of men homozygous for the MS 2756A!G variant, those carrying the CBS 844ins68 allele had lower homocysteine concentrations than those lacking the insertion. A similar analysis for the e¡ects of MTHFR and MS genotypes suggested that the homocysteine-increasing e¡ect of both variants was additive. For all of these gene -gene e¡ects, the possible involvement of nutritional status was explored but these e¡ects were not substantially altered by these adjustments. Recently, Feix et al. 128 reported that the 2756A!G transition in combination with the MTHFR 677TT/1298AA and 677CT/1298AC is associated with high homocysteine concentrations. However, when they con¢ned their analysis to only the MS variant, they did not observe any association with homocysteine concentrations whatsoever. 128 Thus, although the majority of studies on genetic regulation of plasma homocysteine concentrations have been con¢ned to a single polymorphism, the few studies on gene-gene interaction document a polygenic in£uence on plasma homocysteine concentrations. Therefore, studies that do not con¢ne their analyses to a single polymorphism will be of great interest for studying the genetic basis of hyperhomocysteinaemia.
Gene-environment interactions
Many studies have demonstrated the importance of nutritional regulation of plasma homocysteine concentrations. 24 An interaction between micronutrient de¢ciencies and variants in genes regulating homocysteine metabolism has in particular been demonstrated for the 677C!T polymorphism in the MTHFR gene. 91 Since many nutritional factors such as folate or B vitamins play an important role in homocysteine metabolism as cofactors or substrate, further research on an interactive role between these factors and genetic variation is warranted.
In conclusion, many variants in the genes involved in homocysteine metabolism have now been studied. Besides the 677C!T polymorphism in the MTHFR gene, which has a pronounced e¡ect on plasma homocysteine concentrations, several other variants have been reported to in£uence homocysteine metabolism by a¡ecting enzyme activity (e.g. the MTHFR 1298A!C and CBS 31-bp VNTR), or by showing an association with plasma homocysteine concentrations (e.g. the MS 2756A!G, cSHMT 1420C!T, the MTRR 66A!G and the GCPII1561C!T variants). Despite the large number of publications on the association between elevated plasma homocysteine concentrations and various polymorphisms, our understanding of the aetiology of moderately elevated plasma homocysteine concentrations is still incomplete. Although there is a wide agreement that both genetic and nutritional factors are implicated, all the genetic variations described so far do not seem to explain the genetic component of hyperhomocysteinaemia in the general population. In a recent study, Kluijtmans et al. 130 found that these known polymorphisms explained only 9% of the overall variance in the plasma homocysteine concentrations, which was almost entirely explained by the MTHFR 677C!T polymorphism. It is possible that more genetic variation in genes involved in homocysteine metabolism is present. Genes that could be eligible as candidate genes are involved in transport or absorption of folate, such as the folate-binding protein, or cofactors such as vitamin B 12 and B 6 . Also (other) variants, in the genes mentioned here, can be further examined for their role and e¡ect on homocysteine concentrations and/or CVD risk. In addition to the genes of the key enzymes in homocysteine metabolism, other genes coding for enzymes that might be relevant for homocysteine homeostasis could be important. Therefore, a genome-wide approach using linkage and association studies in large family cohorts is a powerful tool in the discovery of unknown polymorphisms that in£uence homocysteine concentrations in humans.
